To complement its prostate cancer franchise, which is currently lead by Zytiga® (abiraterone acetate), Janssen Biotech, the wholly owned subsidiary of Johnson & Johnson,has entered into a collaboration and license agreement with US-based Tesaro for the global (excluding Japan) development and future marketing rights of the PARP inhibitor, niraparib, for use in prostate cancer in a deal worth up to US$500 M. As a part of transaction, Johnson & Johnson Innovation (JJDC) is undertaking an equity investment in Tesaro.